MedicGo
CD137 / CD137 ligand signalling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases.
Metadata
Journaljournal of autoimmunity6.658Date
2020 Jun 04
4 months ago
Type
Review
Journal Article
Volume
2020-Aug / 112 : 102499
Author
Wong HY 1, Schwarz H 2
Affiliation
  • 2. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, 117593, Singapore; Immunology Programme, Life Sciences Institute, National University of Singapore, 117456, Singapore. Electronic address: [email protected]
Doi
PMIDMESH
Abstract
CD137 (TNFRSF9, 4-1BB) is a potent co-stimulatory molecule of the tumour necrosis factor receptor superfamily (TNFRSF) that is expressed by activated T cells. CD137/CD137 ligand (CD137L) signalling primarily induces a potent cell-mediated immune response, while signalling of cell surface-expressed CD137L into antigen presenting cells enhances their activation, differentiation and migratory capacity. Studies have shown that bidirectional CD137/CD137L signalling plays an important role in the pathogenesis of autoimmune diseases. This review discusses the mechanisms how CD137/CD137L signalling contributes to immune deviation of helper T cell pathways in various murine models, and the potential of developing immunotherapies targeting CD137/CD137L signalling for the treatment of autoimmune diseases.
Keywords: Autoimmunity CD137 CD137L Immunotherapy Soluble CD137
Fav
Like
Download
Share
Export
Cite
6.7
J Autoimmunjournal of autoimmunity
Metadata
LocationEngland
FromACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD

No Data

© 2017 - 2020 Medicgo
Powered by some medical students